Syntric Medical, a spinout from Eindhoven University of Technology, has raised €500,000 in pre-seed funding from four investors for a robotic system that guides needle placement using live CT images. The round stays open to further investors until 31 December 2026.
Syntric Medical builds a patented robotic platform that helps an interventional radiologist place a needle correctly on the first attempt, even in very small targets. The system works with live CT images and accounts for the way an abnormality shifts as the patient breathes, according to a press release from BOM, the Brabant development agency and one of the backers.
The company is starting with lung biopsies, where small spots can be hard to sample because of respiratory movement. An inconclusive biopsy can mean a repeat procedure and a delay in diagnosis, BOM said. Syntric Medical plans to apply the same technology to other procedures in the chest and abdomen where breathing makes needle placement difficult, with liver ablation given as an example.
The deal
The €500,000 pre-seed round comes from BOM, imec.istart, Graduate Ventures and RoundOne. BOM said each investor brings its own expertise to the company, and that the round remains open to investors until 31 December 2026.
The money is earmarked for further development and preclinical validation of the platform. Syntric Medical will also seek early feedback from the US Food and Drug Administration through a pre-submission process, and test how much demand there is among healthcare providers and what they would be willing to pay. BOM noted that these steps are meant to validate the technology and its route to adoption, and do not amount to regulatory approval.
"With this investment we can move our technology a step closer to the patient," said chief executive Joric Oude Vrielink.
The investors' view
Auke van den Hout, managing partner at Graduate Ventures, pointed to the team's robotics background at TU/e combined with a clear view of what radiologists need. Paul Vernooij, investment manager at BOM, framed the deal as part of the agency's strategy of investing early to help medical technology reach patients and to build the region's medtech ecosystem.
What comes next
The next steps set out in the release are preclinical validation, the FDA pre-submission and a check on provider demand and willingness to pay. The company's stated mission is to make accurate needle placement simple across interventional radiology, with lung cancer diagnosis as the starting point.
Original source: BOM, "Syntric Medical aims to make lung cancer diagnosis more reliable" (press release)





